Gold prices just lower; monthly gains on track
Lee Kevin, the Chief Executive Officer of Bicycle Therapeutics PLC (NASDAQ:BCYC), recently executed a sale of company shares, according to a regulatory filing. On April 2 and April 3, Kevin sold a total of 5,669 ordinary shares, generating approximately $43,612. The shares were sold at prices ranging from $7.48 to $8.02 per share. The transaction comes as the stock trades near its 52-week low, having declined about 67% over the past year. According to InvestingPro analysis, the stock appears undervalued at current levels.
The transactions were conducted to cover statutory tax withholding obligations related to the vesting and settlement of restricted stock units, as mandated by the CEO’s award agreement. Following these sales, Kevin retains direct ownership of 486,265 shares in Bicycle Therapeutics. While the company maintains strong liquidity with a current ratio of 13.8, InvestingPro analysis reveals 12 additional key insights about BCYC’s financial health and market position in their comprehensive Pro Research Report.
In other recent news, Bicycle Therapeutics has announced a series of leadership changes, with Felix J. Baker, Ph.D., stepping in as chairman of the Board of Directors. The company has also made strides in its oncology efforts, with Alessandro Riva, M.D., joining the Board and Fabrice André, M.D., Ph.D., being appointed to the Clinical Advisory Board. Financially, Bicycle Therapeutics reported a strong cash position of approximately $880 million, expected to support operations into the second half of 2027. JMP Securities has maintained a Market Outperform rating with a $26 price target, highlighting the company’s robust financial position and upcoming corporate milestones. Jefferies, however, adjusted its price target for Bicycle Therapeutics from $53 to $42, while maintaining a Buy rating, citing promising Phase 1 data for Zele+pembo in urothelial carcinoma. Rodman & Renshaw also reaffirmed a Buy rating and a $33 price target, emphasizing the company’s progress in its clinical pipeline. Bicycle Therapeutics is advancing its lead program, zelenectide pevedotin, in a global Phase 2/3 trial for metastatic urothelial cancer. The company is also preparing for additional trials targeting NECTIN-4 gene-amplified cancers and expects to release human imaging data from its Bicycle-radio conjugate programs in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.